FDA Approves RETEVMO — Eli Lilly and Company

Eli Lilly and Company received FDA approval for RETEVMO (selmetinib) to treat patients with advanced RET-fusion-positive meningiomas, a significant milestone for the biopharmaceutical giant’s rare oncology franchise. This approval addresses a high unmet medical need in neuro-oncology, diversifying Eli Lilly’s revenue streams beyond its core metabolic portfolio.